Cardiac drug-psychotropic drug update

James J. Strain, Anwarul Karim, Gina Caliendo, Jeffrey D. Alexis, R. Sandlin Lowe, Valentin Fuster

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


This is an update from the report - Cardiac Drug and Psychotropic Drug Interactions: Significance and Recommendations - published in this journal in November-December 1999. As mentioned in that article there has been an explosion of new drugs both in psychiatry and cardiology without a sufficient understanding of their potential interactions. Also there is a need for methods to update drug interactions on an ongoing basis. This report describes: 1) examples of actual adverse interactions from clinical cases that move beyond some of the hypothesized contraindications included in the 2000 millennium publication; 2) confirmation of previous adverse interactions reported if they strengthen the earlier findings; 3) listing of new drugs, e.g., sildenafil (viagra) now commonly prescribed by psychiatrists and cardiologists; 4) reports explaining and/or refining mechanisms of adverse interactions; and 5) cautions and important associated phenomenon of either a cardiac or a psychotropic drug, e.g., valproic acid and cases of life-threatening pancreatitis. Methods of publicizing the new knowledge of cardiac drug-psychotropic drug interactions, e.g., the Internet and web sites are described.

Original languageEnglish
Pages (from-to)283-289
Number of pages7
JournalGeneral Hospital Psychiatry
Issue number5
StatePublished - 2002


  • Adverse drug reactions
  • Cardiac drugs
  • Drug interactions
  • Psychotropic drugs
  • Update methods


Dive into the research topics of 'Cardiac drug-psychotropic drug update'. Together they form a unique fingerprint.

Cite this